Direct medical costs associated with atopic diseases among young children in Thailand

Ngamphaiboon, Jarungchit; Kongnakorn, Thitima; Detzel, Patrick; Sirisomboonwong, Krittawan; Wasiak, Radoslaw

doi:10.3111/13696998.2012.698671

Cited by 13 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86 Monitoring and laboratory tests were associated with a cost of ฿962; inpatient care had a cost of ฿564. 86 These relatively small costs compared with the cost in some other countries may in part be a result of climate differences: Thailand weather is generally warm with a high degree of humidity, possibly aiding in keeping the skin hydrated. 86 Last, in the first study of its kind conducted in India, the costs associated with AD in an outpatient setting showed that mean total cost over a 6-month period (calculated as the sum of the mean caregiver cost, provider cost and indirect costs) was found to be`6235.…”

Section: Economic Burdenmentioning

confidence: 99%

Burden of atopic dermatitis in Asia

Tsai

Rajagopalan

Chu

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense pruritus and eczematous lesions. It is considered one of the most common chronic conditions, with an estimated global prevalence of nearly 230 million. As in the rest of the world, prevalence of atopic dermatitis has been increasing in Asian countries over the last few decades. This increased prevalence in Asian countries has been attributed to factors such as rapid urbanization, increasingly Westernized lifestyles, and improved standards of living and education. As a result, it is important to understand the increasing burden of disease in Asian countries and the differences between the countries in terms of epidemiology, diagnostic criteria, management, quality of life and economic burden.

show abstract

Section: Economic Burdenmentioning

confidence: 99%

Burden of atopic dermatitis in Asia

Tsai

Rajagopalan

Chu

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…A total of 26 studies (33%) were considered to have conducted a form of cost‐of‐illness study, one of which used a model developed in Excel (Microsoft, Redmond, WA, U.S.A.) . Most of these studies evaluated the cost of eczema within children, with only two papers stating explicitly that they were evaluating adults with eczema . Other papers did not specify the population age, with 11 stating a population of patients with eczema .…”

Section: Resultsmentioning

confidence: 99%

Understanding economic evidence for the prevention and treatment of atopic eczema

2019

View full text Add to dashboard Cite

Summary Background Atopic eczema is an inflammatory skin condition, with a similar impact on health‐related quality of life as other chronic diseases. Increasing pressures on resources within the National Health Service increase the importance of having good economic evidence to inform their allocation. Objectives To educate dermatologists about economic methods with reference to currently available economic evidence on eczema. Methods The role of different types of economic evidence is illustrated by evidence found in a systematic literature search conducted across 12 online databases up to 22 May 2017. Primary empirical studies either reporting the results of a cost‐of‐illness study or evaluating the cost, utility or full economic evaluation of interventions for preventing or treating eczema were included. Two reviewers independently assessed studies for eligibility and performed data abstraction, with disagreements resolved by a third reviewer. Evidence tables of results were produced for narrative discussion. The reporting quality of economic evaluations was assessed. Results Seventy‐eight studies (described in 80 papers) were deemed eligible. Thirty‐three (42%) were judged to be economic evaluations, 12 (15%) cost analyses, six (8%) utility analyses, 26 (33%) cost‐of‐illness studies and one a feasibility study (1%). The calcineurin inhibitors tacrolimus and pimecrolimus, as well as barrier creams, had the most economic evidence available. Partially hydrolysed infant formula was the most commonly evaluated prevention. Conclusions The current level of economic evidence for interventions aimed at preventing and treating eczema is limited compared with that available for clinical outcomes, suggesting that greater collaboration between clinicians and economists might be beneficial.

show abstract

“…The lowest costs were observed in Thailand [35] (USD 199 across all severities, ranging from USD 124 among mild cases to USD 968 among severe cases), in part because only direct costs were reported.…”

Section: Economic Burden Of Pediatric Ad In the Asia Pacific Regionmentioning

confidence: 99%

“…A total of 5 published studies were identified (table 1): 2 for Australia [32,33], 1 for South Korea [34], 1 for Thailand [35] and 1 for the Philippines [36], which required reanalyses to generate some of the outcomes presented herein. These studies were further complemented with unpublished analyses conducted by some of the coauthors in Indonesia, Malaysia and Singapore [37].…”

Section: Economic Burden Of Pediatric Ad In the Asia Pacific Regionmentioning

confidence: 99%

Treatment of Childhood Atopic Dermatitis and Economic Burden of Illness in Asia Pacific Countries

2015

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common chronic inflammatory skin condition in children. In Asia, the prevalence of AD is increasing, which is largely attributed to environmental and socioeconomic factors including family income, parental education, lifestyle and metropolitan living. Current clinical guidelines recommend a stepped approach in the management of eczema in children, with treatment steps tailored to the severity of the eczema. To address the skin barrier dysfunction, skin hydration and the application of emollients is essential. There is evidence supporting the use of bleach baths as an antimicrobial therapy against Staphylococcus aureus. In patients in whom topical treatment fails, wet wrap therapy may be considered as a treatment option before considering systemic therapies. In the second part of this article, the economic burden of AD is addressed. AD not only negatively impacts the child's quality of life but also that of the whole family and is associated with a burden on health-care costs and society. AD in an infant will lead to frequent additional visits to the pediatrician, to additional and partially expensive treatment costs and, in rare cases, to hospitalization. It is thus of utmost importance to define efficient strategies to not only treat AD but also to decrease the risk of developing the disease.

show abstract

Direct medical costs associated with atopic diseases among young children in Thailand

Abstract: Atopic diseases in young children are associated with substantial burden in direct medical costs to Thailand. These costs can be diminished through nutritional intervention recognized to effectively decrease the incidence of atopic diseases.

Cited by 13 publications

References 20 publications

Burden of atopic dermatitis in Asia

Burden of atopic dermatitis in Asia

Understanding economic evidence for the prevention and treatment of atopic eczema

Treatment of Childhood Atopic Dermatitis and Economic Burden of Illness in Asia Pacific Countries

Contact Info

Product

Resources

About